Issue Navigation
-
Review
-
1-7
New insights into the molecular basis of lactase non-persistence/ persistence: a brief review
Kuchay RAH
Drug Discov Ther. 2020; 14(1):1-7.
DOI: 10.5582/ddt.2019.01079
-
8-13
Matsumoto Y, Takahashi M, Sekimizu K
Drug Discov Ther. 2020; 14(1):8-13.
DOI: 10.5582/ddt.2020.01002
-
14-20
Goto M, Nozawa M, Wada Y, Shimokawa K, Ishii F
Drug Discov Ther. 2020; 14(1):14-20.
DOI: 10.5582/ddt.2020.01004
-
21-26
Takayanagi Y, Koike A, Kubota H, Wu L, Nishi I, Sato A, Aonuma K, Kawakami Y, Ieda M
Drug Discov Ther. 2020; 14(1):21-26.
DOI: 10.5582/ddt.2019.01082
-
27-34
Kanno C, Murayama R, Abe-Doi M, Takahashi T, Shintani Y, Nogami J, Komiyama C, Sanada H
Drug Discov Ther. 2020; 14(1):27-34.
DOI: 10.5582/ddt.2019.01094
-
35-41
Suzuki R, Gunarta IK, Boldbaatar J, Erdenebaatar P, Odongoo R, Yoshioka K
Drug Discov Ther. 2020; 14(1):35-41.
DOI: 10.5582/ddt.2020.01001
-
42-49
Usefulness of next-generation DNA sequencing for the diagnosis of urinary tract infection
Ishihara T, Watanabe N, Inoue S, Aoki H, Tsuji T, Yamamoto B, Yanagi H, Oki M, Kryukov K, Nakagawa S, Inokuchi S, Ozawa H, Imanishi T
Drug Discov Ther. 2020; 14(1):42-49.
DOI: 10.5582/ddt.2020.01000
-
50-53
Association of moderately abnormal behavior and administered neuraminidase inhibitors
Sugawara T, Ohkusa Y, Taniguchi K, Miyazaki C, Momoi MY, Okabe N
Drug Discov Ther. 2020; 14(1):50-53.
DOI: 10.5582/ddt.2019.01091
-
54-57
Efficacy of Chinese prescription Kangen-karyu for patient with metabolic syndrome
Kitazawa T, Park CH, Hiratani K, Choi JS, Yokozawa T
Drug Discov Ther. 2020; 14(1):54-57.
DOI: 10.5582/ddt.2020.01003
-
58-60
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Dong LY, Hu SS, Gao JJ
Drug Discov Ther. 2020; 14(1):58-60.
DOI: 10.5582/ddt.2020.01012